On Thursday, October 29, 2026, the US Department of Labor finalized a pharmacy benefit manager transparency rule, which is required reading for all employers that sponsor group health plans.
What the Final Rule Requires
Under the rule, pharmacy
CMS Revises Protocol Form to Ease Disclosures of Missed In-Office Imaging Notices
The Centers for Medicare & Medicaid Services (CMS) recently posted revised forms for its voluntary self-referral disclosure protocol (SRDP), the process Medicare providers and suppliers use to self-disclose and resolve actual or potential violations of the physician self-referral law (Stark
Webcast: Life Sciences Trends and Compensation Planning for 2027, Regulatory Update, and Strategies for Investor Outreach
This recorded session provides HR and Total Rewards leaders with critical market intelligence to inform 2027 compensation, talent, and workforce planning decisions. Gibson Dunn lawyers and Aon/Radford leaders explore merit and salary increase trends, workforce mobility, hiring activity, and other
DOJ and HHS-OIG Coordinate Healthcare Fraud Self-Disclosures; DOJ Launches Fraud Whistleblower Rewards Program
New policy offers companies single-disclosure path to seek the benefits of both DOJ’s criminal corporate enforcement policy and HHS-OIG’s Self-Disclosure Protocol; appropriate path depends on whether conduct may be criminal. Separately, DOJ announced the Fraud Whistleblower Incentive Program, which offers
Telehealth Expansion, Cross-State Licensure and Transactional Considerations
Originally published in Healthcare News and Healthcare Michigan.
Reprinted with Permission.
One of the most lasting changes brought about by the COVID-19 pandemic has been the widespread adoption of telehealth. Between 2019 and 2021, physician use of telemedicine increased
The Growing PFAS Focus in Europe and the UK – Strategies for Life Sciences Companies
PFAS, or per- and polyfluoroalkyl substances – which are widely used across industries and in life sciences applications, from cosmetics and food-contact-material to medical devices and pharmaceuticals – have become an increasing focus of regulatory scrutiny across Europe. In the
Virtual and Digital Health Digest – October 2026
Welcome to the latest installment of Arnold & Porter’s Virtual and Digital Health digest. This digest covers key virtual and digital health regulatory and public policy developments during September 2026 from the EU and UK.
The most significant development this
Texas Reaches $45M Settlement With Gilead to Resolve Medicaid Kickback Allegations Over Patient-Support Programs
The state of Texas secured a $45 million settlement from Gilead Sciences Inc. over allegations that its patient-support programs improperly encouraged prescriptions for drugs covered by Medicaid. This case highlights both how patient-support services can draw scrutiny when they provide
Johns Hopkins Bayview asked an AI operator to delete patient data and has not said whether the operator did
Editor’s Note: Johns Hopkins Bayview Medical Center in Baltimore began mailing notices Oct. 22 to about 3,182 patients after an employee uploaded a spreadsheet of their information to a public artificial intelligence tool the hospital had not approved. The file
Madras HC bows down to mother’s “painful” decision; permits termination of 31-week pregnancy after detecting serious foetal brain abnormalities
Madras High Court: In a matter concerning termination of a 31-week pregnancy following the detection of substantial foetal abnormalities, a Single Judge Bench of P.T. Asha, J. quashed the Medical Board’s refusal to permit termination of a pregnancy beyond 24